Vienna - Delayed Quote EUR

Thermo Fisher Scientific Inc. (TMOF.VI)

Compare
487.60 -2.95 (-0.60%)
At close: November 26 at 5:32 PM GMT+1
Loading Chart for TMOF.VI
DELL
  • Previous Close 490.55
  • Open 489.75
  • Bid 486.65 x --
  • Ask 488.45 x --
  • Day's Range 486.10 - 489.75
  • 52 Week Range 440.30 - 573.30
  • Volume 0
  • Avg. Volume 1
  • Market Cap (intraday) 187.88B
  • Beta (5Y Monthly) 0.79
  • PE Ratio (TTM) 32.06
  • EPS (TTM) 15.21
  • Earnings Date Jan 31, 2025 - Feb 5, 2025
  • Forward Dividend & Yield 1.45 (0.30%)
  • Ex-Dividend Date Dec 13, 2024
  • 1y Target Est --

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

www.thermofisher.com

122,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TMOF.VI

View More

Performance Overview: TMOF.VI

Trailing total returns as of 11/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TMOF.VI
1.38%
S&P 500
26.24%

1-Year Return

TMOF.VI
9.30%
S&P 500
32.07%

3-Year Return

TMOF.VI
13.69%
S&P 500
28.08%

5-Year Return

TMOF.VI
75.60%
S&P 500
92.16%

Compare To: TMOF.VI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TMOF.VI

View More

Valuation Measures

Annual
As of 11/26/2024
  • Market Cap

    187.88B

  • Enterprise Value

    215.33B

  • Trailing P/E

    32.03

  • Forward P/E

    21.64

  • PEG Ratio (5yr expected)

    1.95

  • Price/Sales (ttm)

    4.63

  • Price/Book (mrq)

    3.99

  • Enterprise Value/Revenue

    5.31

  • Enterprise Value/EBITDA

    19.55

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.48%

  • Return on Assets (ttm)

    4.67%

  • Return on Equity (ttm)

    12.94%

  • Revenue (ttm)

    42.37B

  • Net Income Avi to Common (ttm)

    6.14B

  • Diluted EPS (ttm)

    15.21

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.65B

  • Total Debt/Equity (mrq)

    72.33%

  • Levered Free Cash Flow (ttm)

    6.78B

Research Analysis: TMOF.VI

View More

Company Insights: TMOF.VI

Research Reports: TMOF.VI

View More

People Also Watch